2,910 nm erbium-doped fluoride fiber laser for treating advanced perioral lines and wrinkles

Evaluation of the 2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles

This trial will test a 2,910 nm mid-infrared fiber laser to reduce advanced perioral lines and wrinkles in adults aged 50 to 80.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 50 Years to 80 Years
• Sex: All
• Sponsor: FA Corporation (Industry-sponsored)
• Locations: 1 site (Houston, Texas)
• Trial ID: NCT07222397 on ClinicalTrials.gov

What this trial studies

Eligible participants receive up to two full-face resurfacing treatments with the 2,910 nm UltraClear erbium-doped fluoride fiber laser, spaced 6–8 weeks apart, with focused treatment of perioral lines. Effectiveness will be measured at 1 and 3 months after treatment using investigator-rated wrinkle and elastosis scales and blinded independent photographic reviewers. Safety, adverse events, overall aesthetic improvement, and patient satisfaction will be tracked throughout follow-up. Participants must meet inclusion criteria such as Fitzpatrick skin type I–IV and FWS Class II–III and comply with study restrictions and visits.

Who should consider this trial

Good fit: Ideal candidates are adults 50–80 years old with Fitzpatrick skin types I–IV and moderate-to-advanced perioral wrinkling (FWS Class II–III) who are fit for full-face ablative laser resurfacing and can attend follow-up visits.

Not a fit: Patients with darker skin types (Fitzpatrick V–VI), only mild lines, active skin infections, contraindications to ablative lasers, or inability to follow study restrictions are unlikely to benefit.

Why it matters

Potential benefit: If successful, the treatment could meaningfully reduce perioral lines and improve cosmetic appearance with quantifiable patient satisfaction.

How similar studies have performed: Ablative erbium lasers have demonstrated wrinkle and texture improvement in prior studies, though the specific 2,910 nm fiber-glass UltraClear delivery is a newer platform with less published evidence.

Eligibility criteria

Inclusion Criteria:

1. Fitzpatrick skin type I-IV.
2. Male or female.
3. Subjects must be between 50 and 80 years of age.
4. Subjects must have the ability to receive up to two full face resurfacing laser treatment with specific focus on advanced perioral lines and wrinkles.
5. Subjects must read, understand, and sign the Informed Consent Form.
6. Subjects must be willing and able to comply with all follow-up visit requirements.
7. Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator.
8. Subjects must be rated as Class II or Class III based on the Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS).
9. Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion.
10. Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study.

Exclusion Criteria:

1. Subjects must not have active localized or systemic infections.
2. Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atrophic dermatitis or immunologic abnormalities such as vitiligo.
3. Subjects must not have had treatments with 5FU, diclofenac, imiquimod, steroids, retinoids, or PDT within 1-month prior to enrollment.
4. Subjects must not currently be taking Accutane or have taken Accutane within the last 1-month.
5. Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications.
6. Subjects must not have had previous surgery and/or fat transfer in the treatment area within the last 6-months.
7. Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area.
8. Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area.
9. Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area.
10. Subjects must not have had neurotoxins within the last 3-months in the treatment area.
11. Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12 months.
12. Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling, or energy-based device treatment in the treatment area within the last 3 months.
13. Subject must not have had an ablative laser treatment in the treatment area within the last 6 months.
14. Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.
15. Subject must not have active sunburn or excessively tanned skin.
16. Subjects must not be pregnant or breastfeeding, think they may be pregnant or are trying to get pregnant during the study.

Where this trial is running

Houston, Texas

• Dermatology & Laser Surgery Center — Houston, Texas, United States (Recruiting)

Study contacts

• Principal investigator: Paul Friedman, MD — Director, Dermatology & Laser Surgery Center Clinical Assistant Professor of Dermatology, UT Medical School
• Study coordinator: Mary Dick, MD

Conditions Photodamaged Skin; Rhytids; Lines Skin; Wrinkles and Rhytides